Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies

Purpose Complement alternative pathway (AP) dysregulation has been implicated in geographic atrophy, an advanced form of age-related macular degeneration. Danicopan is an investigational, first-in-class inhibitor of factor D, an essential AP activation enzyme. We assessed danicopan distribution to the posterior segment of the eye after oral dosing. Methods Tissue distribution of drug-derived radioactivity was evaluated using whole-body autoradiography following oral administration of [14C]-danicopan to pigmented and albino rats. Pharmacokinetics and ocular tissue distribution were studied in pigmented and albino rabbits following single and multiple oral dosing of danicopan. The melanin binding property was characterized in vitro. Results Radioactivity was distributed widely in rats and became nonquantifiable in most tissues 24 hours postdose except in the pigmented rat uvea (quantifiable 672 hours postdose). Danicopan binding to melanin was established in vitro. After single dosing, the maximum concentration (Cmax) and area under the curve (AUC) in neural retina and plasma were similar in both rabbit types. After multiple dosing, AUC in neural retina was 3.4-fold higher versus plasma in pigmented rabbits. Drug levels in choroid/Bruch's membrane (BrM)/retinal pigment epithelium (RPE) were similar to plasma in albino rabbits but higher in pigmented rabbits: Cmax and AUC were 2.9- and 23.8-fold higher versus plasma after single dosing and 5.8- and 62.7-fold higher after multiple dosing. In pigmented rabbits, ocular tissue exposures slowly declined over time but remained quantifiable 240 hours postdose. Conclusions The results demonstrate that danicopan crosses the blood–retina barrier and binds melanin reversibly, leading to a higher and more sustained exposure in melanin-containing ocular tissues (choroid/BrM/RPE) and in the neural retina as compared to in plasma after repeated oral dosing in pigmented animals. Translational Relevance These findings suggest that oral danicopan possesses potential for treating geographic atrophy because AP dysregulation in the posterior segment of the eye is reported to be involved in the disease pathogenesis.

[1]  P. Dugel,et al.  Complement cascade inhibition in geographic atrophy: a review , 2022, Eye.

[2]  T. Dryja,et al.  Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration , 2021, Investigative ophthalmology & visual science.

[3]  Aaron Y. Lee,et al.  Evolving treatment patterns and outcomes of neovascular age-related macular degeneration over a decade. , 2021, Ophthalmology. Retina.

[4]  J. Maciejewski,et al.  Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria , 2020, Haematologica.

[5]  B. Joondeph,et al.  C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. , 2020, Ophthalmology.

[6]  Philip J Rosenfeld,et al.  Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. , 2020, Ophthalmology.

[7]  A. Urtti,et al.  Establishment of an In Vitro-In Vivo Correlation for Melanin Binding and the Extension of the Ocular Half-Life of Small Molecule Drugs. , 2019, Molecular pharmaceutics.

[8]  P. Mattei,et al.  Understanding Molecular Drivers of Melanin Binding To Support Rational Design of Small Molecule Ophthalmic Drugs. , 2018, Journal of medicinal chemistry.

[9]  P. Hughes,et al.  Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations , 2018, Pharmaceutical Research.

[10]  A. Urtti,et al.  Melanin targeting for intracellular drug delivery: Quantification of bound and free drug in retinal pigment epithelial cells , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Srinivas R. Sadda,et al.  Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials , 2018, JAMA ophthalmology.

[12]  Mary Joseph,et al.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches☆ , 2018, Advanced drug delivery reviews.

[13]  A. Urtti,et al.  Implications of melanin binding in ocular drug delivery☆ , 2017, Advanced drug delivery reviews.

[14]  A. Urtti,et al.  Melanin binding study of clinical drugs with cassette dosing and rapid equilibrium dialysis inserts , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[15]  Paul Mitchell,et al.  The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. , 2017, Ophthalmology.

[16]  B. Yaspan,et al.  Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration , 2017, Science Translational Medicine.

[17]  Ursula Schmidt-Erfurth,et al.  THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET , 2017, Retina.

[18]  A. Urtti,et al.  Pharmacokinetic aspects of retinal drug delivery , 2017, Progress in Retinal and Eye Research.

[19]  Guangwei Yang,et al.  Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome , 2016, Haematologica.

[20]  Shusheng Wang,et al.  Current therapeutic developments in atrophic age-related macular degeneration , 2015, British Journal of Ophthalmology.

[21]  A. Rimpelä Ocular melanin binding of drugs: in vitro binding studies , 2014 .

[22]  Kang Zhang,et al.  Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. , 2014, Ophthalmology.

[23]  U. Schraermeyer,et al.  Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes , 2014, British Journal of Ophthalmology.

[24]  Cynthia A. Toth,et al.  Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. , 2013, JAMA.

[25]  P. Coffey,et al.  Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease. , 2013, Investigative ophthalmology & visual science.

[26]  山城 健児 Age-Related Eye Disease Study 2 (特集 臨床において必要なサプリメントの知識) , 2012 .

[27]  K. Wakamatsu,et al.  Structure of Melanins , 2011 .

[28]  P. Heiduschka,et al.  Penetration of bevacizumab through the retina after intravitreal injection in the monkey. , 2007, Investigative ophthalmology & visual science.

[29]  K. Wakamatsu,et al.  Comparisons of the Structural and Chemical Properties of Melanosomes Isolated from Retinal Pigment Epithelium, Iris and Choroid of Newborn and Mature Bovine Eyes¶ , 2005, Photochemistry and photobiology.

[30]  E. Solon,et al.  Methods determining phosphor imaging limits of quantitation in whole-body autoradiography rodent tissue distribution studies affect predictions of 14C human dosimetry. , 2001, Journal of pharmacological and toxicological methods.

[31]  H. Kolbe,et al.  Technical validation of radioluminography systems. , 2000, Regulatory toxicology and pharmacology : RTP.

[32]  K. Heimann,et al.  Current understanding on the role of retinal pigment epithelium and its pigmentation. , 1999, Pigment cell research.

[33]  P. Zane,et al.  Physicochemical Factors Associated with Binding and Retention of Compounds in Ocular Melanin of Rats: Correlations Using Data from Whole-Body Autoradiography and Molecular Modeling for Multiple Linear Regression Analyses , 1990, Pharmaceutical Research.

[34]  N. Lindquist,et al.  Accumulation of Chorio-retinotoxic Drugs in the Foetal Eye , 1970, Nature.

[35]  A. M. Potts THE REACTION OF UVEAL PIGMENT IN VITRO WITH POLYCYCLIC COMPOUNDS. , 1964, Investigative ophthalmology.

[36]  Jason A. Wiles,et al.  Discovery and Development of the Oral Complement Factor D Inhibitor ACH-4471. , 2019, Current medicinal chemistry.

[37]  K. Gadde,et al.  Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Clinical utility of phentermine/topiramate (QsymiaTM) combination for the treatment of obesity , 2013 .

[38]  A. Mitra,et al.  Ocular drug delivery. , 2010, The AAPS journal.

[39]  Jennifer I. Lim,et al.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. , 2001, Archives of ophthalmology.

[40]  R. Ings,et al.  The melanin binding of drugs and its implications. , 1984, Drug metabolism reviews.